Farxiga Cost in Nevada 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Farxiga Cost in Nevada in 2026?

The retail list price for Farxiga in Nevada sits at approximately $620 per month for a 30-tablet supply of the 10 mg dose in 2026. That figure reflects AstraZeneca's wholesale acquisition cost and is what most cash-pay patients see before any discount is applied. Few Nevada patients pay the full list price. Manufacturer cards, GoodRx-type discount platforms, and telehealth-affiliated pricing programs can all push the number lower, sometimes significantly.

Dapagliflozin is available only as a brand-name product in the United States. No small-molecule generic has received FDA approval. Because of that, normal pharmacy generic substitution cannot occur, and price competition at retail has been limited. The FDA's current dapagliflozin label documents the approved dosage forms and indications.

Prices at individual Nevada pharmacies do fluctuate. A major-chain pharmacy in Las Vegas may quote a slightly different cash price than an independent pharmacy in Reno or a telepharmacy serving rural Clark County. Calling ahead or using a real-time pricing tool before filling is advisable.

Nevada Medicaid Coverage for Farxiga

Nevada Medicaid does not cover Farxiga as of early 2026. The Nevada Division of Welfare and Supportive Services (DWSS) publishes a Preferred Drug List (PDL) for the Medicaid managed care program, and dapagliflozin currently sits off-formulary without a standard prior-authorization pathway leading to approval for most recipients.

That gap is clinically significant. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001). [1] Patients managing heart failure with reduced ejection fraction on a Medicaid budget face a real access barrier when a drug with that size of effect sits off-formulary.

Alternatives available on the Nevada Medicaid PDL for type 2 diabetes include metformin, glipizide, and sitagliptin (covered with restrictions). For heart failure with reduced ejection fraction, sacubitril/valsartan and certain beta-blockers remain accessible. None replicate dapagliflozin's exact mechanism.

Medicaid coverage policies change annually. Patients or prescribers can submit a prior authorization request on a case-by-case basis; medical-necessity exceptions have succeeded in some states, though Nevada's prior-authorization rate for off-formulary SGLT2 inhibitors is not publicly reported.

Commercial Insurance Coverage in Nevada

Most commercial insurance plans in Nevada do cover Farxiga, though tier placement, prior-authorization requirements, and copay vary substantially by carrier and plan year. [2]

Large employer group plans under ERISA tend to place Farxiga on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A Tier 3 placement commonly produces a 30-day copay of $40 to $110 after the deductible is met. Tier 4 placement may push the copay to $100 to $200 or higher per fill.

Nevada exchange plans sold through Nevada Health Link (the state's ACA marketplace) vary by insurer. Anthem, Centene, and UnitedHealthcare all operate plans in Nevada; each publishes a formulary accessible through Nevada Health Link's comparison tool. Checking the 2026 formulary before plan selection is the only way to know a specific drug tier.

Prior authorization is common for heart failure and CKD indications across Nevada commercial plans. Prescribers typically must document an HbA1c for the diabetes indication, or submit echocardiographic data (ejection fraction) for the HFrEF indication, before approval is granted.

The American Heart Association's 2022 guideline update explicitly includes SGLT2 inhibitors as Class I, Level A therapy for symptomatic HFrEF, which provides clinical backing for prior authorization appeals. [3]

The AstraZeneca Savings Card: How It Works in Nevada

AstraZeneca operates the Farxiga Savings Card program for commercially insured patients who meet eligibility criteria. Eligible patients can pay as little as $0 per month for a 30-day supply, with a maximum savings of up to $150 per fill depending on plan type. The savings card is available through the AstraZeneca patient support portal and can be applied at participating Nevada pharmacies.

Key eligibility rules for 2026:

• The patient must have commercial (private) insurance. Medicaid, Medicare Part D, and CHIP recipients are not eligible.
• Patients must be U.S. residents and must be prescribed Farxiga for an FDA-approved indication.
• The card typically covers up to 12 fills per year.

Nevada residents without commercial insurance, or those enrolled in Medicare Part D, need alternative assistance. AstraZeneca's separate AZ&Me Prescription Savings program offers free medication to patients below certain income thresholds. In 2025, the program served patients with household incomes at or below 600% of the federal poverty level ($90,840 for a single person). Income and program limits may change for 2026.

Compounded Dapagliflozin in Nevada: Legal Status and Cost

Compounded dapagliflozin is legal to prescribe and dispense in Nevada when prepared by a licensed 503A compounding pharmacy. 503A refers to the section of the Federal Food, Drug, and Cosmetic Act governing traditional compounding pharmacies that prepare medications for individual patient prescriptions. [4]

503A pharmacies may compound dapagliflozin for patients with a valid prescription, provided the compound is not commercially available in an identical form, the prescriber has identified a specific patient need (such as a different dose, excipient avoidance, or suspension form), and the pharmacy is properly licensed in Nevada.

The Nevada State Board of Pharmacy licenses and inspects 503A pharmacies operating within the state. Out-of-state 503A pharmacies shipping into Nevada must be licensed in their home state and comply with Nevada's non-resident pharmacy permit requirements.

Cost for compounded dapagliflozin at a 503A pharmacy varies. Some telehealth-affiliated compounding programs offer it at prices well below the brand list price. Patients should verify that any compounding pharmacy they use carries PCAB accreditation or equivalent quality documentation, since compounded formulations are not FDA-approved for potency, purity, or bioequivalence in the same way a branded tablet is.

One practical note: compounded dapagliflozin will not be covered by commercial insurance or Medicaid. The cost benefit must be weighed against the absence of insurance coverage and the absence of FDA bioequivalence data for the specific compounded formulation.

HealthRX Nevada Cost Decision Framework for Dapagliflozin:

Use this sequence to identify the lowest-cost access path:

1. Check your specific plan's formulary for dapagliflozin/Farxiga before assuming coverage.
2. If covered on commercial insurance, apply the AstraZeneca Savings Card at checkout to reduce the copay to as low as $0.
3. If on Nevada Medicaid, request a prior authorization for medical necessity. If denied, ask your prescriber whether an alternative covered SGLT2 inhibitor (such as empagliflozin, if added to the PDL) meets your clinical need.
4. If uninsured or underinsured and income-eligible, apply to AZ&Me before paying cash.
5. If none of the above options produce affordable access and your prescriber has a documented clinical rationale, ask about a licensed Nevada 503A pharmacy that compounds dapagliflozin.
6. Do not purchase dapagliflozin from international websites or unlicensed online pharmacies. Authenticity and dosing cannot be verified.

Telehealth Prescribing of Farxiga in Nevada

Nevada permits telehealth prescribing of Farxiga. A licensed Nevada prescriber or an out-of-state prescriber who holds a Nevada telemedicine registration may conduct a synchronous audio-video evaluation and, if clinically appropriate, issue a prescription for dapagliflozin. [5]

Nevada passed significant telehealth expansion legislation during and after the COVID-19 public health emergency. The Nevada Telehealth Act (NRS Chapter 629) allows audio-video visits to substitute for in-person encounters for most non-scheduled prescriptions, which includes Farxiga. Dapagliflozin is not a controlled substance, so DEA special registration requirements do not apply.

Telehealth platforms that operate in Nevada and prescribe cardiometabolic medications commonly use the 10 mg once-daily dose for type 2 diabetes and for HFrEF, consistent with the DAPA-HF dosing protocol. [1] Some platforms support same-day prescription transmission to local Nevada pharmacies or to mail-order pharmacies that ship within Nevada.

Patients seeking telehealth access should confirm that the platform employs a licensed Nevada prescriber or one holding a Nevada telemedicine registration, and that the visit includes a review of relevant labs (eGFR, urinalysis, HbA1c as indicated) before prescribing. Dapagliflozin is contraindicated when eGFR falls below 25 mL/min/1.73 m2 for the diabetes indication per the FDA label.

Why Farxiga's Price Stays High Without a Generic

Dapagliflozin was first approved by the FDA in January 2014 for type 2 diabetes. [6] AstraZeneca's U.S. patent protection has kept generic entrants out of the market; as of early 2026, no Paragraph IV certification has produced an approved generic. The absence of generic competition is the primary driver of the $620/month list price Nevada patients see.

The SGLT2 inhibitor class as a whole has faced similar pricing dynamics. Empagliflozin (Jardiance, Eli Lilly/Boehringer Ingelheim) and canagliflozin (Invokana, Janssen) also lack U.S. generics as of this writing, and all three brand-name agents carry comparable list prices.

The DECLARE-TIMI 58 trial (N=17,160) demonstrated that dapagliflozin reduced hospitalizations for heart failure by 27% (HR 0.73; 95% CI 0.61 to 0.88) among patients with type 2 diabetes and either established cardiovascular disease or multiple risk factors. [7] That outcome data, combined with the DAPA-CKD trial results showing a 39% reduction in the risk of sustained eGFR decline or renal failure in patients with CKD (N=4,304), has cemented dapagliflozin's clinical position. [8] The price, however, reflects patent economics, not the magnitude of benefit.

What Nevada Patients With CKD Should Know About Coverage

The FDA approved dapagliflozin for chronic kidney disease (with or without type 2 diabetes) in April 2021, based on the DAPA-CKD trial. [8] Nevada's Medicaid program has not added CKD as a pathway to formulary coverage. Commercial insurers vary: some Nevada plans added the CKD indication to their prior-authorization approval criteria after the FDA expanded the label; others have not updated their criteria.

The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD gives SGLT2 inhibitors a Grade 1A recommendation for patients with type 2 diabetes and CKD who have eGFR 20 mL/min/1.73 m2 or greater. [9] Grade 1A is the guideline's highest confidence level, which gives prescribers strong footing when filing prior authorization appeals for Nevada commercial plans that have not yet updated their criteria.

Patients with CKD and eGFR between 25 and 45 mL/min/1.73 m2 are an important group: the diabetes indication is no longer approved below eGFR 45, but the CKD indication extends to eGFR 25. Getting the correct indication documented on the prescription and prior authorization form can determine whether coverage is approved or denied.

Comparing Dapagliflozin to Other SGLT2 Inhibitors on Cost in Nevada

Empagliflozin (Jardiance) and canagliflozin (Invokana) carry similar list prices in Nevada, around $590 to $640 per month. No SGLT2 inhibitor in the class currently has a cost advantage at list price in 2026.

The clinical differentiation between agents is modest. The 2023 ACC/AHA Heart Failure Guideline does not preferentially recommend one SGLT2 inhibitor over another for HFrEF; it recommends the class. [10] For a Nevada patient whose commercial plan covers Jardiance on Tier 3 but places Farxiga on Tier 4, switching to empagliflozin with prescriber approval may cut the monthly copay by $50 to $80. That formulary arbitrage is worth discussing with both the prescriber and the pharmacist.

Ertugliflozin (Steglatro) tends to sit in a similar price range and has a narrower indication set (type 2 diabetes only, no approved HF or CKD indications as of 2026), making it a poor substitute for patients with those comorbidities.

Practical Steps for Nevada Residents to Reduce Farxiga Cost in 2026

Getting the price down requires working two or three levers simultaneously rather than relying on any single program.

Start with an insurance formulary check. Log into your plan's member portal, search for dapagliflozin or Farxiga, and note the tier and any step-therapy requirement. If the plan requires failing metformin or an older agent first, confirm with your prescriber whether documented contraindications or prior use can waive that requirement.

Apply the AstraZeneca Savings Card at the pharmacy counter on the same day you pick up the prescription. The card does not require pre-registration in most cases; the pharmacist enters a BIN/PCN number during processing. Patients who have not applied the card at prior fills may be able to use it retroactively at some pharmacies, though this is not guaranteed.

Ask about 90-day supplies. Many Nevada commercial plans offer a lower per-day cost for 90-day fills at mail-order pharmacies compared to 30-day fills at retail. The AstraZeneca Savings Card is also accepted at most mail-order pharmacies.

If cost remains prohibitive after the card, contact the HealthRX care team for a Nevada-specific cost consultation. A brief review of your insurance, income, and clinical history can identify whether AZ&Me, a 503A compounded option, or formulary substitution with empagliflozin makes more sense for your situation.

The KDIGO 2022 guideline states: "We recommend treatment with an SGLT2 inhibitor for patients with type 2 diabetes and CKD who have eGFR ≥20 mL/min/1.73 m2 (1A)." [9] Getting that on paper during a prior authorization appeal can convert a denial into an approval for Nevada commercial plan members.

According to the American Diabetes Association's 2024 Standards of Care, SGLT2 inhibitors with proven cardiovascular benefit are recommended as part of glucose-lowering therapy independent of HbA1c for patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk (Grade A). [2]